SCHEMBL2176605

SCHEMBL2176605

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(-c5ccccc5)cc4)nc3)cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DEGS1 O15121 1/20 0.46
DGAT1 O75907 5/20 0.46
SDCBP O00560 2/20 0.43
SDC2 P34741 2/20 0.43
MAP3K5 Q99683 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
WNT3A P56704 1/20 0.41
EGFR P00533 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181144 0.91 DEGS1 (0.44) DEGS1DGAT1SDCBPSDC2MAP3K5
SCHEMBL2178173 0.91 DEGS1 (0.44) DEGS1DGAT1SDCBPSDC2MAP3K5
SCHEMBL2180419 0.90 MAP3K5 (0.43) DEGS1SDCBPSDC2MAP3K5MEN1
SCHEMBL2177079 0.90 MAP3K5 (0.43) DEGS1SDCBPSDC2MAP3K5MEN1
SCHEMBL2179464 0.88 THRB (0.43) WNT3ATHRB
SCHEMBL13719015 0.87 LMNA (0.48) DEGS1SDCBPSDC2LMNA
SCHEMBL2180113 0.87 LMNA (0.48) DEGS1SDCBPSDC2LMNA
SCHEMBL2178118 0.87 LMNA (0.48) DEGS1SDCBPSDC2LMNA
SCHEMBL2178354 0.87 GCK (0.38) DEGS1SDCBPSDC2MAP3K5
SCHEMBL13718837 0.84 PTPN1 (0.47) DGAT1SDCBPSDC2MAP3K5WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DEGS1 209/4885DGAT1 1/4885SDCBP 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.